{"id":324308,"date":"2026-08-03T10:00:11","date_gmt":"2026-08-03T10:00:11","guid":{"rendered":"https:\/\/www.europesays.com\/se\/324308\/"},"modified":"2026-08-03T10:00:11","modified_gmt":"2026-08-03T10:00:11","slug":"sobis-vd-guido-oelkers-lamnar-i-borjan-av-2027-gar-till-biontech-uppdatering","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/324308\/","title":{"rendered":"Sobis vd Guido Oelkers l\u00e4mnar i b\u00f6rjan av 2027 &#8211; g\u00e5r till Biontech (uppdatering)"},"content":{"rendered":"<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">(l\u00e4gger till detaljer om hans nya uppdrag)\n <\/p>\n<p>Guido Oelkers l\u00e4mnar rollen som vd och koncernchef f\u00f6r l\u00e4kemedelsbolaget Sobi senast vid utg\u00e5ngen av januari 2027 f\u00f6r ett uppdrag utanf\u00f6r bolaget. Styrelsen inleder omedelbart arbetet med att utse en eftertr\u00e4dare. Det framg\u00e5r av ett pressmeddelande.\n <\/p>\n<p>Oelkers har lett Sobi i n\u00e4ra tio \u00e5r. Bolagets verksamhet, strategi och finansiella m\u00e5l \u00e4r of\u00f6r\u00e4ndrade.\n <\/p>\n<p>Tyska l\u00e4kemedelsbolaget Biontech meddelar att Oelkers utsetts till ny vd och tilltr\u00e4der senast den 1 februari 2027. Han eftertr\u00e4der medgrundaren Ugur Sahin, som l\u00e4mnar vd-posten men kvarst\u00e5r i bolaget f\u00f6r att st\u00f6dja \u00f6verl\u00e4mningen.\n <\/p>\n<p>Enligt Biontech, som \u00e4r noterat p\u00e5 Nasdaq i USA, ska Oelkers leda bolagets fortsatta utveckling till ett globalt biofarmabolag med flera godk\u00e4nda produkter. Bolaget lyfter fram hans erfarenhet av att bygga globala l\u00e4kemedelsverksamheter och utveckla produktportf\u00f6ljer inom bland annat onkologi och immunologi.<br \/>\n <br class=\"col-start-2\"\/><\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Stefan Linn\u00e9r<br \/>\n <br class=\"col-start-2\"\/><br \/>\n stefan.linner@finwire.se<br \/>\n <br class=\"col-start-2\"\/><br \/>\n Nyhetsbyr\u00e5n Finwire<\/p>\n","protected":false},"excerpt":{"rendered":"(l\u00e4gger till detaljer om hans nya uppdrag) Guido Oelkers l\u00e4mnar rollen som vd och koncernchef f\u00f6r l\u00e4kemedelsbolaget Sobi&hellip;\n","protected":false},"author":2,"featured_media":324309,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[65],"tags":[34343,72,70,71,34,31,33,32,30,11925],"class_list":["post-324308","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ekonomi","tag-biontech","tag-business","tag-economy","tag-ekonomi","tag-se","tag-svenska","tag-sverige","tag-sweden","tag-swedish","tag-swedish-orphan-biovitrum"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/117030998755627973","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/324308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=324308"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/324308\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/324309"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=324308"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=324308"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=324308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}